Idarubicin Hikma

Idarubicin, the active ingredient in Idarubicin Hikma, is an anthracycline presented as an injectable solution for intravenous use. It treats acute myeloid leukemia in adult patients and is also used off‑label for certain acute lymphoblastic leukemia cases. It is administered under the supervision of a qualified oncologist and is part of standard chemotherapy protocols for hematologic malignancies.

GNH USA supplies Idarubicin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Idarubicin is an anthracycline chemotherapy agent used in the treatment of acute leukemias.

- Acute Myeloid Leukemia (AML): induces remission by targeting rapidly dividing leukemic cells. - Acute Lymphoblastic Leukemia (ALL) – off‑label: may be employed in refractory cases to achieve cytoreduction. - Acute leukemia (overall): incorporated into induction regimens to reduce disease burden before consolidation therapy.

Idarubicin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Alopecia (hair loss) - Fatigue and weakness - Myelosuppression (decreased blood cell counts) - Mucositis (inflammation of the mouth lining) - Diarrhea

Serious or Rare Side Effects: - Cardiotoxicity (heart failure, reduced ejection fraction) - Severe neutropenia with febrile episodes - Hemorrhagic complications due to thrombocytopenia - Hepatic toxicity (elevated transaminases) - Secondary malignancies (therapy‑related leukemia) - Severe infusion‑related reactions (hypotension, anaphylaxis).

When using Idarubicin, clinicians should observe several safety measures.

- Cardiac monitoring: baseline and periodic echocardiograms to detect early cardiotoxicity. - Hematologic monitoring: regular complete blood counts to manage myelosuppression. - Liver function assessment: monitor transaminases and bilirubin before each cycle. - Pregnancy risk: avoid use in pregnant women; discuss contraception with women of child‑bearing potential. - Concomitant nephrotoxic agents: adjust therapy if renal impairment is present. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicin can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Co‑administration with other cardiotoxic agents (e.g., doxorubicin, epirubicin): increased risk of cardiac damage. - Live attenuated vaccines: heightened infection risk due to immunosuppression. - High‑dose chest radiation therapy: synergistic cardiotoxic effects.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations of idarubicin. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic exposure. - Anticoagulants (e.g., warfarin, heparin): enhanced bleeding risk from thrombocytopenia.